Aarti Pharmalabs Limited — Q3 FY26
Aarti Pharmalabs reported Q3 FY26 revenue of ₹5,425 crore, up 15% YoY, but EBITDA fell to ₹103 crore (down 10% YoY) and PAT dropped to ₹44 crore (down 41% YoY), reflecting margi...
bearish
high
✓ Verified against BSE filing
Indian management teams deliver on roughly 12% of specific earnings-call promises. A low score does not indicate dishonesty — it reflects how aspirational forward guidance typically is.
Q1 FY26
Zanthin derivative capacity expansion to 9,000 MT by H2 FY26
Brownfield expansion from 5,000 to 9,000 MT per annum will be commissioned in phases during H2 FY26.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1
Q1 FY26
Atali greenfield plant commercial production by end of Q2 FY26
Mechanical completion of Phase 1 at Atali is done; commercial production will commence towards end of Q2 FY26, with full ramp-up by end of FY26.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1